The Steroid Refactory Acute Graft-Versus-Host Disease market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage pipeline products will significantly revolutionize the Steroid Refactory Acute Graft-Versus-Host Disease market dynamics.

DelveInsight’s “Steroid Refactory Acute Graft-Versus-Host Disease Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Steroid Refactory Acute Graft-Versus-Host Disease, historical and forecasted epidemiology as well as the Steroid Refactory Acute Graft-Versus-Host Disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

To Know in detail about the Steroid Refactory Acute Graft-Versus-Host Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Steroid Refactory Acute Graft-Versus-Host Disease Market Forecast

Some of the key facts of the Steroid Refactory Acute Graft-Versus-Host Disease Market Report:

• The Steroid Refactory Acute Graft-Versus-Host Disease market size is anticipated to grow with a significant CAGR during the study period (2019-2032)

• In May 2025, MaaT Pharma (EURONEXT: MAAT), a clinical-stage biotech company specializing in Microbiome Ecosystem Therapies™ (MET) to improve cancer patient survival through immune modulation, announced that following the EMA Pediatric Committee’s approval of its Pediatric Investigation Plan (PIP), the Data and Safety Monitoring Board (DSMB) has completed its final safety review of the pivotal Phase 3 ARES trial. This single-arm, open-label, multicenter European study evaluates the efficacy and safety of MaaT013 in patients with acute Graft-versus-Host Disease (GI-aGvHD) involving the gastrointestinal tract, who are receiving third-line treatment after being refractory to steroids and either refractory or intolerant to ruxolitinib.

• In December 2024, The FDA has approved remestemcel-L-rknd (Ryoncil) for treating pediatric patients aged two months and older with steroid-refractory acute graft-versus-host disease (GVHD), according to an agency announcement. The approval is supported by results from the multicenter, prospective, single-arm MSB-GVHD001 trial (NCT02336230), which evaluated the allogeneic bone marrow-derived MSC therapy in 54 children with steroid-refractory acute GVHD following allogeneic hematopoietic stem cell transplantation (HSCT).

• In December 2024, The FDA has granted approval to Mesoblast’s allogeneic bone marrow-derived mesenchymal stromal cell (MSC) therapy, remestemcel-L, for treating steroid-refractory acute graft-versus-host disease (GvHD) in children aged two months and older.

• The biopsy may help confirm Steroid Refactory Acute Graft-Versus-Host Disease diagnosis, but lacks sensitivity and specificity

• In around 35–50% of patients, aGVHD becomes refractory to systemic steroid therapy

• Key Steroid Refactory Acute Graft-Versus-Host Disease Companies: MaaT Pharma, medac GmbH, AltruBio Inc., Incyte Corporation, and others

• Key Steroid Refactory Acute Graft-Versus-Host Disease Therapies: MC0518, Neihulizumab, T-Guard, Ruxolitinib, Apraglutide, and others

• The Steroid Refactory Acute Graft-Versus-Host Disease diagnosis is carried through laboratory analysis, imaging, and or endoscopic

Steroid Refactory Acute Graft-Versus-Host Disease Overview

Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD) is a serious and life-threatening complication that occurs after an allogeneic stem cell or bone marrow transplant. In this condition, the donated immune cells attack the recipient’s body tissues. Normally, steroids are the first line of treatment to control this immune response. However, in steroid-refractory cases, patients either do not respond to steroids or their symptoms worsen, making the disease harder to manage. SR-aGVHD often affects organs such as the skin, liver, and gastrointestinal tract and requires alternative therapies to improve survival and quality of life.

Request a sample for the Steroid Refactory Acute Graft-Versus-Host Disease Market Report:

https://www.delveinsight.com/report-store/steroid-refactory-acute-graft-versus-host-disease-gvhd-market

Steroid Refactory Acute Graft-Versus-Host Disease Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Steroid Refactory Acute Graft-Versus-Host Disease Epidemiology Segmentation:

The Steroid Refactory Acute Graft-Versus-Host Disease market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Prevalence of Steroid Refactory Acute Graft-Versus-Host Disease

• Prevalent Cases of Steroid Refactory Acute Graft-Versus-Host Disease by severity

• Gender-specific Prevalence of Steroid Refactory Acute Graft-Versus-Host Disease

• Diagnosed Cases of Episodic and Chronic Steroid Refactory Acute Graft-Versus-Host Disease

Download the report to understand which factors are driving Steroid Refactory Acute Graft-Versus-Host Disease epidemiology trends @ Steroid Refactory Acute Graft-Versus-Host Disease Epidemiological Insights

Steroid Refactory Acute Graft-Versus-Host Disease Market

The dynamics of the Steroid Refactory Acute Graft-Versus-Host Disease market are anticipated to change in the coming years owing to the expected launch of emerging therapies such as Itacitinib, MaaT013, and others during the forecasted period 2019-2032.

Steroid Refactory Acute Graft-Versus-Host Disease Therapies and Emerging Therapies

• MC0518: MaaT Pharma

• Neihulizumab: medac GmbH

• T-Guard: AltruBio Inc

• Ruxolitinib: Incyte Corporation

To know more about Steroid Refactory Acute Graft-Versus-Host Disease treatment, visit @ Steroid Refactory Acute Graft-Versus-Host Disease Medications

Steroid Refactory Acute Graft-Versus-Host Disease Market Drivers

• Rising Incidence of Hematopoietic Stem Cell Transplantation (HSCT)

• High Unmet Medical Need

• Regulatory Support & Designations

• Ongoing Clinical Trials & Emerging Therapies

• Increased Awareness & Diagnosis

Steroid Refactory Acute Graft-Versus-Host Disease Market Barriers

• Complex Pathophysiology

• High Cost of Treatment

• Limited Patient Pool

• Adverse Effects of Therapies

• Delayed Diagnosis and Referral

Scope of the Steroid Refactory Acute Graft-Versus-Host Disease Market Report

• Study Period: 2019–2032

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Steroid Refactory Acute Graft-Versus-Host Disease Companies: MaaT Pharma, medac GmbH, AltruBio Inc., Incyte Corporation, and others

• Key Steroid Refactory Acute Graft-Versus-Host Disease Therapies: MC0518, Neihulizumab, T-Guard, Ruxolitinib, Apraglutide, and others

• Therapeutic Assessment: Steroid Refactory Acute Graft-Versus-Host Disease current marketed and Steroid Refactory Acute Graft-Versus-Host Disease emerging therapies

• Steriod Refactory Acute Graft-Versus Host Disease Market Dynamics: Steroid Refactory Acute Graft-Versus-Host Disease market drivers and barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Unmet Needs, KOL’s views, Analyst’s views, Steroid Refactory Acute Graft-Versus-Host Disease Market Access and Reimbursement

Discover more about therapies set to grab major Steroid Refactory Acute Graft-Versus-Host Disease market share @ Steroid Refactory Acute Graft-Versus-Host Disease Treatment Landscape

Table of Contents

1. Steroid Refactory Acute Graft-Versus-Host Disease Market Report Introduction

2. Executive Summary for Steroid Refactory Acute Graft-Versus-Host Disease

3. SWOT analysis of Steroid Refactory Acute Graft-Versus-Host Disease

4. Steroid Refactory Acute Graft-Versus-Host Disease Patient Share (%) Overview at a Glance

5. Steroid Refactory Acute Graft-Versus-Host Disease Market Overview at a Glance

6. Steroid Refactory Acute Graft-Versus-Host Disease Disease Background and Overview

7. Steroid Refactory Acute Graft-Versus-Host Disease Epidemiology and Patient Population

8. Country-Specific Patient Population of Steroid Refactory Acute Graft-Versus-Host Disease

9. Steroid Refactory Acute Graft-Versus-Host Disease Current Treatment and Medical Practices

10. Steroid Refactory Acute Graft-Versus-Host Disease Unmet Needs

11. Steroid Refactory Acute Graft-Versus-Host Disease Emerging Therapies

12. Steroid Refactory Acute Graft-Versus-Host Disease Market Outlook

13. Country-Wise Steroid Refactory Acute Graft-Versus-Host Disease Market Analysis (2019–2032)

14. Steroid Refactory Acute Graft-Versus-Host Disease Market Access and Reimbursement of Therapies

15. Steroid Refactory Acute Graft-Versus-Host Disease Market drivers

16. Steroid Refactory Acute Graft-Versus-Host Disease Market barriers

17. Steroid Refactory Acute Graft-Versus-Host Disease Appendix

18. Steroid Refactory Acute Graft-Versus-Host Disease Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/